Payment overview · 2025
General Payments
$820.01
45 reported records · 16 companies
Healthcare provider profile · identity verified
Jeffrey M Craft, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPARTANBURG, SC · NPI 1114907128
Verified facts
What the public records show
CMS Open Payments records show Jeffrey M Craft, MD received $820.01 in general payments during 2025 across 45 reported records.
Novartis Pharmaceuticals Corporation accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $185.25 | 22.6% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$61.40 | 7.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.36 | 7.1% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.65 | 6.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.19 | 6.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.04 | 6.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.22 | 5.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.97 | 5.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $42.87 | 5.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.74 | 5.2% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $42.56 | 5.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.49 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.53 | 3.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.32 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.80 | 3.3% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $21.62 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $820.01 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $185.25 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $65.23 | 4 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $61.40 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $56.65 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $49.04 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.01 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.01 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.34 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.11 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 187 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
253 | 51 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
161 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 636 | 181 |
| Atorvastatin Calcium | Atorvastatin Calcium | 606 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 165 |
| Lisinopril | Lisinopril | 463 | 125 |
| Montelukast Sodium | Montelukast Sodium | 458 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 446 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 395 | 109 |
| Omeprazole | Omeprazole | 376 | 102 |
| Gabapentin | Gabapentin | 368 | 117 |
| Metformin Hcl | Metformin Hcl | 354 | 101 |
| Allopurinol | Allopurinol | 263 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 60 |
| Farxiga | Dapagliflozin Propanediol | 253 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 244 | 66 |
| Tramadol Hcl | Tramadol Hcl | 239 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 238 | 65 |
| Alprazolam | Alprazolam | 227 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 55 |
| Losartan Potassium | Losartan Potassium | 216 | 60 |
| Spironolactone | Spironolactone | 198 | 46 |
| Ezetimibe | Ezetimibe | 188 | 64 |
| Eliquis | Apixaban | 187 | 35 |
| Furosemide | Furosemide | 186 | 64 |
| Pregabalin | Pregabalin | 185 | 52 |
| Valsartan | Valsartan | 182 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 54 |
| Potassium Chloride | Potassium Chloride | 168 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 22 |
| Mounjaro | Tirzepatide | 161 | 37 |
| Simvastatin | Simvastatin | 159 | 41 |
| Trazodone Hcl | Trazodone Hcl | 149 | 44 |
| Jardiance | Empagliflozin | 148 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 148 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 44 |
| Pioglitazone Hcl | Pioglitazone Hcl | 147 | 40 |
| Carvedilol | Carvedilol | 144 | 39 |
| Vascepa | Icosapent Ethyl | 134 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 38 |
| Fenofibrate | Fenofibrate | 126 | 28 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 125 | 36 |
| Clonazepam | Clonazepam | 121 | 25 |
| Ozempic | Semaglutide | 118 | 22 |
| Famotidine | Famotidine | 109 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 30 |
| Sertraline Hcl | Sertraline Hcl | 101 | 31 |
| Lorazepam | Lorazepam | 97 | 20 |
| Memantine Hcl | Memantine Hcl | 93 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 23 |
| Repatha Sureclick | Evolocumab | 85 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 32 |
| Icosapent Ethyl | Icosapent Ethyl | 76 | 28 |
| Buspirone Hcl | Buspirone Hcl | 75 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 22 |
| Aripiprazole | Aripiprazole | 70 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 70 | 17 |
| Benazepril Hcl | Benazepril Hcl | 68 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 23 |
| Diazepam | Diazepam | 67 | suppressed |
| Synthroid | Levothyroxine Sodium | 67 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 65 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 17 |
| Linzess | Linaclotide | 63 | 18 |
| Azithromycin | Azithromycin | 62 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Celecoxib | Celecoxib | 54 | 13 |
| Januvia | Sitagliptin Phosphate | 54 | 14 |
| Mirtazapine | Mirtazapine | 54 | 18 |
| Glipizide | Glipizide | 50 | 13 |
| Donepezil Hcl | Donepezil Hcl | 49 | 17 |
| Meloxicam | Meloxicam | 49 | 18 |
| Atenolol | Atenolol | 48 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 48 | suppressed |
| Nitroglycerin | Nitroglycerin | 47 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 14 |
| Amoxicillin | Amoxicillin | 44 | 42 |
| Teriparatide | Teriparatide | 44 | suppressed |
| Creon | Lipase/Protease/Amylase | 42 | suppressed |
| Indapamide | Indapamide | 42 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 11 |
| Sucralfate | Sucralfate | 39 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 13 |
| Fluconazole | Fluconazole | 31 | 21 |
| Ramipril | Ramipril | 31 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 23 |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Nexletol | Bempedoic Acid | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Topiramate | Topiramate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Prednisone | Prednisone | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | 11 |
| Epinephrine | Epinephrine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nucynta | Tapentadol Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $820.01 · 45 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, BREZTRI, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, ELIQUIS, EVENITY, FLOWTRIEVER CATHETER, S, INTELLIS ADAPTIVESTIM, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, Tymlos, VOQUEZNA, Veozah, Wegovy, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error